$ 4.68
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved;...
Company Valuation
Based on key historical and expected multiples, the stock is fairly valued relative to its peers. In particular, the stock is overpriced on P/E, of fair value on EV/EBITD
Target Price
The average target price of ORGO is 8.5 and suggests 82% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
